- Conditions
- Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Vaginal Carcinoma
- Interventions
- Adavosertib, Cisplatin, External Beam Radiation Therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Sacramento, California • Aurora, Colorado • Lexington, Kentucky + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,037
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Gastrointestinal Tumors
- Interventions
- Minnelide™ 001
- Drug
- Lead sponsor
- Minneamrita Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Minneapolis, Minnesota
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 129
- States / cities
- Anaheim, California • Arroyo Grande, California • Baldwin Park, California + 90 more
- Conditions
- Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Cisplatin, Computed Tomography, Conventional Magnetic Resonance Imaging, Gemcitabine Hydrochloride
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Auburn, California • Berkeley, California • Fremont, California + 27 more
- Conditions
- Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Extrahepatic Bile Duct Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IVA Extrahepatic Bile Duct Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Extrahepatic Bile Duct Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Unresectable Extrahepatic Bile Duct Carcinoma
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ricolinostat
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Hypertension
- Interventions
- Salt loading, Hydrochlorothiazide (HCTZ)
- Procedure · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Glucose Intolerance, Gastric Bypass Surgery
- Interventions
- Ursodeoxycholic Acid, Placebos
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasal Cavity Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Paranasal Sinus Squamous Cell Carcinoma, Locally Advanced Sinonasal Squamous Cell Carcinoma, Maxillary Sinus Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Tampa, Florida • Chicago, Illinois • Fairway, Kansas + 13 more
- Conditions
- Hypertension, Obstructive Sleep Apnea
- Interventions
- Dietary sodium
- Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 48 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Intraocular Lens Replacement
- Interventions
- OMS302, Placebo
- Drug
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
- Conditions
- Medulloblastoma
- Interventions
- Cisplatin, Craniospinal Irradiation, Cyclophosphamide, Involved-Field Radiation Therapy, Laboratory Biomarker Analysis, Lomustine, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate
- Drug · Radiation · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
- Conditions
- Heart Failure
- Interventions
- Sodium reduction, omega 3 and lycopene supplements, rice bran oil capsules, Generic dietary feedback from
- Behavioral · Dietary Supplement
- Lead sponsor
- Terry Lennie
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Louisville, Kentucky
- Conditions
- Corneal Opacity
- Interventions
- Mitomycin-C, Fluorometholone 1% topical ocular steroid
- Drug
- Lead sponsor
- United States Naval Medical Center, San Diego
- Federal
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- NIDDM, Obesity
- Interventions
- Metformin Extended Release (ER) Oral Tablet, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Fiberoptic bronchoscopy, blood draw, intravenous catheter
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Exercise Physiology, Nutritional Supplementation
- Interventions
- Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate), placebo beverage
- Dietary Supplement · Other
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 692
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more
- Conditions
- Overweight and Obesity
- Interventions
- 24-hour ambulatory blood pressure, Liberal salt diet
- Diagnostic Test · Dietary Supplement
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
- Drug
- Lead sponsor
- Ranbaxy Laboratories Limited
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 889
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
- Interventions
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 174
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more
- Conditions
- Obesity, Insulin Resistance
- Interventions
- Metabolically abnormal obese - Mediterranean diet, Metabolically abnormal obese - Low carbohydrate ketogenic diet, Metabolically abnormal obese - Plant-based, very-low-fat diet, Annual Follow-up Visits
- Other · Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hot Flashes
- Interventions
- Brisdelle (paroxetine mesylate), Placebo capsules
- Drug
- Lead sponsor
- Noven Therapeutics
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 32
- States / cities
- Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more
- Conditions
- Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
- Interventions
- Aminophylline, Placebo
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois